Amyotrophic Lateral Sclerosis Plasma

About Amyotrophic Lateral Sclerosis Plasma

Amyotrophic Lateral Sclerosis Plasma for Neurodegeneration Research

Amyotrophic Lateral Sclerosis Plasma is collected from IRB-consented donors with a clinically confirmed ALS diagnosis and processed within one day of collection to preserve neuronal injury proteins, cytokines, and metabolites. Plasma is an acellular matrix, so this product is intended for soluble-analyte work rather than cell-based assays.

ALS Pathobiology and Why Plasma

ALS is a progressive neurodegenerative disease of upper and lower motor neurons. It is not an autoimmune disease, and its molecular basis is now well defined:

• TDP-43 proteinopathy — cytoplasmic mislocalisation and aggregation of the RNA-binding protein TDP-43 — is the defining pathology in the large majority of cases, placing ALS on a continuum with frontotemporal dementia
• Established genetic causes include the C9orf72 repeat expansion and mutations in SOD1, FUS, and TARDBP, with SOD1 now the target of an approved antisense therapy
• Neurofilament light chain is the best-supported fluid biomarker. Plasma NfL, measurable by ultrasensitive immunoassay, reflects axonal degeneration and is widely used as a pharmacodynamic and prognostic readout in ALS trials
• Phosphorylated neurofilament heavy chain is studied in parallel, and both markers are affected by pre-analytical handling — which is why controlled, documented processing matters for this analyte class
• Secondary neuroinflammation and metabolic change are real features of ALS, so cytokine, lipid, and metabolite panels are legitimate exploratory endpoints alongside neuronal injury markers
• Why plasma: anticoagulated collection avoids the clotting cascade and is the matrix most commonly specified for NfL platforms, supporting large aliquot counts and serial-timepoint designs from a single donor

Donor Stratification Available

• Site of onset: bulbar, upper limb, lower limb, or respiratory
• Familial versus sporadic disease, and known genotype where clinically tested
• Disease duration since symptom onset and since diagnosis
• Rate of progression and functional status where ALSFRS-R scores are documented
• Treatment status, including riluzole, edaravone, or gene-targeted therapy
• Age, sex assigned at birth, race/ethnicity, and respiratory support status
• Matched, age-matched healthy controls available

Product Features

• Research Use Only (RUO) human plasma
• Plasma collected from clinically confirmed amyotrophic lateral sclerosis donors
• Processed within one day of collection
• Choice of anticoagulant available on request
• Serial collections from the same donor available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified amyotrophic lateral sclerosis diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Site of onset, disease duration, and additional ALS-specific clinical metadata available on request

Applications

• Plasma neurofilament light chain and pNfH quantification
• Ultrasensitive immunoassay development and cross-platform validation
• Prognostic and progression-rate biomarker discovery
• Pharmacodynamic biomarker work for gene-targeted and small-molecule therapies
• Proteomic, lipidomic, and metabolomic profiling
• Neuroinflammatory mediator and cytokine panels
• Longitudinal studies using serial timepoints from the same donor
• Comparative studies against age-matched controls and other neurodegenerative cohorts

Other Amyotrophic Lateral Sclerosis Specimen Types

• Amyotrophic Lateral Sclerosis Serum — clotting-independent matrix for protein panels
• Amyotrophic Lateral Sclerosis Whole Blood — fresh, for germline genotyping and same-day cellular assays
• Amyotrophic Lateral Sclerosis PBMC — cryopreserved cells for transcriptomics and iPSC derivation
• Human Cerebrospinal Fluid — for CNS-proximal biomarker work

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering and Customization

Amyotrophic lateral sclerosis plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For healthy-donor controls and the full specimen range, see our human plasma collection.